A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03467867|
Recruitment Status : Active, not recruiting
First Posted : March 16, 2018
Last Update Posted : March 16, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Chronic Lymphocytic Leukemia||Drug: Venetoclax Drug: Rituximab Drug: Rituximab/Hyaluronidase Human||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL|
|Actual Study Start Date :||April 26, 2018|
|Estimated Primary Completion Date :||October 15, 2023|
|Estimated Study Completion Date :||October 15, 2023|
Experimental: Venetoclax + Rituximab
Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
Venetoclax will be administered as described in the reporting arm.
Rituximab (IV) will be administered as described in the reporting arm.
Other Name: Rituxan
Drug: Rituximab/Hyaluronidase Human
Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
Other Name: Rituxan Hycela
- Overall Response Rate (ORR) [ Time Frame: Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) ]Percentage of Participants With Best Overall Response (OR)(Defined as Complete Response [CR], Initial CR [CRi], Nodular Partial Response [nPR], PR) as Assessed by Investigator Determined Using iwCLL Guidelines
- Disease Response [ Time Frame: 12 weeks after Day 1 of last cycle of combination therapy (approximately 5 years, cycle length= 28 days) ]Percentage of Participants With Disease Response (OR, CR, CRi, nPR, PR) as Assessed by Investigator Determined Using iwCLL Guidelines at end of Combination Treatment Visit
- Duration of Responses (DOR) [ Time Frame: Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) ]Duration of Responses (DOR)
- Time to Progression (TTP) [ Time Frame: Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) ]Time to progression will be defined as the time from the date of first dose (date of enrollment if not dosed) to the date of earliest disease progression (per the investigator assessment).
- Progression-Free Survival (PFS) [ Time Frame: Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) ] ]Investigator-Assessed Progression-Free Survival (PFS) Determined Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines
- Overall Survival (OS) [ Time Frame: Baseline up to death (up to approximately 5 years) ]Overall Survival (OS)
- Time to Next Anti-CLL Treatment (TTNT) [ Time Frame: Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) ] ]Time to Next Anti-CLL Treatment (TTNT)
- Percentage of Participants With Minimal Residual Disease (MRD) [ Time Frame: 12 weeks after Day 1 of last cycle of combination therapy (up to approximately 5 years, cycle length= 28 days) ] ]Percentage of Participants With Minimal Residual Disease (MRD) Negativity at End of Combination Treatment Response Visit
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Signed Informed Consent Form
- Ability and willingness to comply with the requirements of the study protocol
- Patient must have diagnosis of CLL that meets published 2008 IWCLL NCI-WG criteria.
- Patient must have relapsed/refractory disease with an indication for treatment.
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2
Adequate hematologic function (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator) defined as follows:
- Hemoglobin (> / =) 9 g/dL
- Absolute neutrophil count (> / =) 1.0 x 109/L
- Platelet count (> / =)75 x 109/L
Adequate renal function, as indicated by:
- Calculated creatinine clearance ≥ 30 mL/min using 24-hour Creatinine Clearance or modified Cockcroft-Gault equation (eCCR; with the use of ideal body mass [IBM] instead of mass)
Adequate liver function, as indicated by:
- AST or ALT (< / =) 2.5 x ULN
- Total bilirubin < 1.5 x ULN (or (< / =) 3 x ULN for patients with documented Gilbert syndrome)
- Female patients who are not of child-bearing potential and female patients of child-bearing potential who have a negative serum pregnancy test within 3 days prior to Cycle 1, Day 1.
- Patients with HIV infection could be included in the study, as long as their disease is under control on anti-retroviral therapy. Precautions should be taken to modify their HAART regimen to minimize drug interaction
- Warfarin is considered a cautionary medication. Patients on warfarin will be encouraged to replace warfarin with other anticoagulants if possible. If it is not possible or patient is not willing to switch, they could still be included in the study with caution.
- Known hypersensitivity to any of the study drugs
- Allogeneic stem cell transplant within the past 1 year.
- Richter's transformation confirmed by biopsy
History of other malignancy that could affect compliance with the protocol or interpretation of results
- Patients with a history of curatively treated basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible.
- Patients with a malignancy that has been treated with surgery alone with curative intent will be included. Individuals in documented remission without treatment for (> / =) 2 years prior to enrollment may be included at the discretion of the investigator.
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient, including renal disease that would preclude chemotherapy administration or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1
Received the following agents within 7 days prior to the first dose of venetoclax:
- Steroid therapy for anti-neoplastic intent
- Strong and moderate CYP3A inhibitors
- Strong and moderate CYP3A inducers
- Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax
- Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
- Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibody
- Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation
- Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing.
- Known infection with human T-cell leukemia virus 1 (HTLV-1)
- Patients with uncontrolled HIV infection
- Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
- Pregnant or lactating, or intending to become pregnant during the study Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drug.
- Recent major surgery (within 6 weeks prior to the start of Cycle 1, Day 1) other than for diagnosis
- Malabsorption syndrome or other condition that precludes enteral route of administration
- Known allergy to both xanthine oxidase inhibitors and rasburicase
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03467867
|United States, District of Columbia|
|Georgetown University Medical Center|
|Washington, District of Columbia, United States, 20007|
|United States, New Jersey|
|John Theurer Cancer Center at Hackensack University Medical Center|
|Hackensack, New Jersey, United States, 07601|
|Responsible Party:||Georgetown University|
|Other Study ID Numbers:||
|First Posted:||March 16, 2018 Key Record Dates|
|Last Update Posted:||March 16, 2023|
|Last Verified:||March 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Chronic Lymphocytic Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Immune System Diseases
Antineoplastic Agents, Immunological
Physiological Effects of Drugs